PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Screening programs”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,189 records · Page 66Linked to original sources

Adherence to the screening program for HBV infection in pregnant women delivering in Greece.

BACKGROUND: Hepatitis B infection (HBV) is a major Public Health Problem. Perinatal transmission can be prevented with the identification of HBsAg(+) women and administration of immunoprophylaxis to their newborns. A national prevention programme for HBV with universal screening of pregnant women and vaccination of infants is in effect since 1998 in Greece. METHODS: To evaluate adherence to the national guidelines, all women delivering in Greece between 17-30/03/03 were included in the study. Trained health professionals completed a questionnaire on demographic data, prenatal or perinatal screening for HBsAg and the implementation of appropriate immunoprophylaxis. RESULTS: During the study period 3,760 women delivered. Prenatal screening for HBsAg was documented in 91.3%. Greek women were more likely to have had prenatal testing. HBsAg prevalence was 2.89% (95%CI 2.3-3.4%). Higher prevalence of HBV-infection was noted in immigrant women, especially those born in Albania (9.8%). Other risk factors associated with maternal HBsAg (+) included young maternal age and absence of prenatal testing. No prenatal or perinatal HBsAg testing was performed in 3.2% women. Delivering in public hospital and illiteracy were identifiable risk factors for never being tested. All newborns of identified HBsAg (+) mothers received appropriate immunoprophylaxis. CONCLUSION: The prevalence of HBsAg in Greek pregnant women is low and comparable to other European countries. However, immigrant women composing almost 20% of our childbearing population, have significant higher prevalence rates. There are still women who never get tested. Universal vaccination against HBV at birth and reinforcement of perinatal testing of all women not prenatally tested should be discussed with Public Health Authorities.

Adult↗

[Cost of a mass screening program for colorectal cancer using the occult blood test].

The Cancer Registry of Burgundy, France, set up a controlled study involving 91,000 people aged 45 to 74 to ascertain the cost-effectiveness of mass screening for colorectal cancer with the Hemoccult test. The aim of this study was to estimate the cost of the first part of the screening campaign, which took place in 1988 and 1989. The overall cost of the campaign was 2,275,589 FF. The cost for the GPs' instruction course was 3.9 percent and the press campaign, 8.4 percent of total costs. The cost related to the distribution or prescription of tests by the GPs was 60.3 percent of the total cost of the campaign. The average cost per test was 39.8 FF when it was distributed by the GPs. The average cost per test was 116.4 FF when bought individually in drugstores or pharmacies. The average cost per test was 70.1 FF when mailing was used. The average cost per test for the analysis was 12.7 FF that is to say 13.7 percent of the total cost. The cost of scientific follow-up and analysis was 13.8 percent. The cost for one person completing the test averaged 92.7 FF. The preliminary results of the cost-effectiveness analysis make it possible to estimate the cost of the mass screening campaign for colorectal cancer. Better cost/effectiveness ratios have already been made according to these results.

Aged↗

Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.

OBJECTIVES: To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database. METHODS: A total of 12,943 men were screened for prostate cancer. Of these, 4458 men had simultaneous measurements of tPSA and cPSA. Height and weight were used to calculate the BMI. The subjects were grouped by decade of age and categorized as either obese or nonobese with a cutoff BMI of 30 kg/m2. The rates of increase in mean tPSA and cPSA between consecutive decades were compared. The relationship among BMI, PSA, and cPSA was also analyzed using multivariate regression analysis. RESULTS: The median age of those screened was 60 years. The median PSA and cPSA was 1.10 and 0.69 ng/dL, respectively. Both serum tPSA and cPSA levels showed an exponential increase with advancing age. The ratio of cPSA/tPSA remained relatively constant at 0.6. Compared with the nonobese cohort, men with a BMI of 30 kg/m2 or more had significantly lower tPSA and cPSA levels across all age groups (P <0.01). The overall odds ratio for all age groups was 1.8 (95% confidence interval 1.2 to 2.3). CONCLUSIONS: Both tPSA and cPSA levels increased with age. Across age groups, men with a greater BMI had significantly lower cPSA and tPSA levels. The clinical significance of age-adjusted cutoff levels for PSA in obese men for the diagnosis of prostate cancer should be explored further in future prospective clinical trials.

Age Factors↗

Group B streptococcus. Is it time for a screening program?

Group B streptococcal infection often causes perinatal sepsis. Early diagnosis is based on a high index of suspicion and laboratory tests. Proposed interventions targeted at the antepartum, intrapartum, and postpartum periods have met with limited success. Screening has not been widely adopted.

Adult↗